<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371445">
  <stage>Registered</stage>
  <submitdate>5/09/2016</submitdate>
  <approvaldate>27/09/2016</approvaldate>
  <actrnumber>ACTRN12616001348448</actrnumber>
  <trial_identification>
    <studytitle>Comparing a-blocker against combination therapy, a-blocker plus Prostenoa, for male non-neurogenic lower urinary tract symptoms treatment.</studytitle>
    <scientifictitle>Evaluating the efficacy of combination scheme a-blocker plus Prostenoa against a-blocker alone for the treatment male non-neurogenic lower urinary tract symptoms. </scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-neurogenic lower urinary tract symptoms in males</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with lower urinary tract symptoms due to BPH will be randomized to receive either oral tablet of any kind of a-blocker (determined by treating doctor) once daily for 6 months or oral tablet of any kind of a-blocker (determined by treating doctor) plus oral capsule of Prostenoa once daily for six months. Monitoring, including International Prostate Symptoms Score, Post Void Residual, and Quality of Life based on SF 36, will take place at 6 and 12 months, after treatment beginning
Recieving treatment checking will be based on drug tablet return.
Prostenoa is a nutricion supplement conisting of Serenoa repens 320mg, Cucurbita pepo 505mg, Lycopenium 0.3mg and Selenium 28mcg per tablet.



.</interventions>
    <comparator>Prostenoa plus any a-blocker / control treatment</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>International Prostate Symptoms Score (IPSS)



</outcome>
      <timepoint>Baseline, 6 and 12 months after start of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Post Void Residual (Bladder Ultrasound)</outcome>
      <timepoint>Baseline, 6 and 12 months after start of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Quality of life (SF 36)</outcome>
      <timepoint>Baseline, 6 and 12 months after start of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>None</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male patients with non-neurogenic lower urinary tract symptoms and International Prostate Symptoms Score over 10.</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Treatment discomfort

Neurogenic male urinary symptoms

Prostate cancer

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>www.randomizer.org, central randomization by computer</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Nil</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>17/10/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>1/09/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaly</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Thessaly</primarysponsorname>
    <primarysponsoraddress>Mezourlo 

41100

Larissa
</primarysponsoraddress>
    <primarysponsorcountry>Greece</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Thessaly</fundingname>
      <fundingaddress>Mezourlo 

41100

Larissa
</fundingaddress>
      <fundingcountry>Greece</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of tis study is to evaluate the efficacy of the combination therapy of a-blocker plus Prostenoa for the treatment of non-neurogenic lower urinary tract symptoms in male patients, comparing to a-blocker alone. Patients will be allocated in two Groups. Group 1 will receive the monotherapy, while Group 2 will receive the combination therapy. Patients will be evaluated after 6 and 12 months, based on International Prostate Symptoms Score, Post Void Residual and Quality of Life.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Scientific Committee University Hospital of Larisa</ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/08/2016</ethicapprovaldate>
      <hrec>30026</hrec>
      <ethicsubmitdate>1/08/2016</ethicsubmitdate>
      <ethiccountry>Greece</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Tzortzis Vasileios</name>
      <address>Urology Profesor, Urology Department of University of Thessaly
Viopolis Mezourlo
41100
Larisa</address>
      <phone>+302413502811</phone>
      <fax />
      <email>tzorvas@otenet.gr</email>
      <country>Greece</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Samarinas</name>
      <address>Urologist, Urology Department of University of Thessaly
Viopolis Mezourlo
41100
Larisa</address>
      <phone>+306946006798</phone>
      <fax />
      <email>mikesamih@hotmail.com</email>
      <country>Greece</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Samarinas</name>
      <address>Urologist, Urology Department of University of Thessaly
Viopolis Mezourlo
41100
Larisa</address>
      <phone>+306946006798</phone>
      <fax />
      <email>mikesamih@hotmail.com</email>
      <country>Greece</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michael Samarinas</name>
      <address>Urologist, Urology Department of University of Thessaly
Viopolis Mezourlo
41100
Larisa</address>
      <phone>+306946006798</phone>
      <fax />
      <email>mikesamih@hotmail.com</email>
      <country>Greece</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>